Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helicon Therapeutics, Inc.
Farmingdale, New York, United States
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Developed small-molecule therapeutics targeting CREB pathway for memory enhancement; advanced HT-0712 (PDE4 inhibitor) to IND in 2004, in-licensed HT-2157 (GALR3) in 2005 and filed IND for HT-1067 (MAO-B) in 2009; no reported clinical trial results post-IND.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Cold Spring Harbor LaboratoryOSI PharmaceuticalsHoffman-LaRocheInflazymeLundbeck
Beyond the preview
Go deeper on Helicon Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helicon Therapeutics, Inc..